4395 -- Cosmetic Safety Amendments Act of 2012

4395 -- Cosmetic Safety Amendments Act of 2012 | Poliscope

Cited source text, amounts, lobbyists, and targets

Legislation in the 112th H.R. 432, the Ban Poisonous Additives Act of 2011( related Senate Bill, S. 136) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill. Continued: Legislation in the 112th S. 847, the Safe Chemicals Act of 2011 The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. H.R. 2359, the Safe Cosmetics Act of 2011 The Breast Cancer Fund supports this legislation to reform the FDA's regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. H.R.4395, the Cosmetic Safety Amendments Act of 2012 The Breast Cancer Fund opposes this legislation as it would further weaken the FDAs ability to regulate the safety of cosmetics. H.R. 4262, the Cosmetics Safety Enhancement Act of 2012 The Breast Cancer Fund opposes this legislation as it is not strong enough to effectively regulate the safety of cosmetics. H.R. 2521, the Endocrine-Disrupting Chemicals Exposure Elimination act of 2011 (Senate version S. 1361) and H.R. 553 Endocrine Disruptor Screening Enhancement Act of 2011 The Breast Cancer Fund supported this legislation as it would increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer. H.R. 1939: Enhancing CPSC Authority and Discretion Act of 2011. The Breast Cancer Fund lobbied for a provision that ensures that phthalates, when necessary in the manufacture of children's toys, are only used safely. H.R. 3067: Accelerating the End of Breast Cancer Act of 2011. The Breast Cancer Fund supported this legislation as it would increase focus on research to prevent, treat, and end breast caner. S. 3237, the Accelerating the End of Breast Cancer Act of 2012. The Breast Cancer Fund supports this legislation as it would increase focus on research to prevent, treat, and end breast cancer. House and Senate Appropriations - The Breast Cancer Fund contacted House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program, opposing appropriations riders limiting the work of the National Toxicology Program's Report on Carcinogens, and increasing support for health tracking and NIEHS programs related to breast cancer research. Future Legislative Proposals: The Breast Cancer Fund continues to meet with staff from various House and Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products. The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. Regulation and Legislative Intent: FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally. Presidents Cancer Panel Report The Breast Cancer Fund communicated with staff in the Executive Office of the President and the Office of Science and Technology Policy regarding the report and recommendations of the President's Cancer Panel, and continues to encourage ongoing efforts by the Executive Branch to raise awareness about breast cancer risk, prevention, and the environment. P.L. 110-314 - The Consumer Product Safety Commission Inprovement Act The Breast Cancer Fund lobbied in support of the provision that bans the use of phthalates in the manufacture of children's toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and are submitting public comments at various stages of the law's implementation. P.L. 110-354 - Breast Cancer and Environmental Research Act of 2008 This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.

Client expense: Not reported · Firm income: $30,000

H.R.4395

DANIEL PENCHINA KATHARINE HUFFMAN RANDI MOORE

Government targets: Consumer Product Safety Commission (CPSC), Environmental Protection Agency (EPA), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), SENATE

ALTICOR INC.client→ALTICOR INC.

2012 · fourth_quarter · Consumer Issues/Safety/Products

Open original LDA filing ↗

Cited source text, amounts, lobbyists, and targets

H.R. 611, to foster transparency about the commercial use of personal information, provide consumers with meaningful choice about the collection, use, and disclosure of such information. H.R. 654, to direct the Federal Trade Commission to prescribe regulations regarding the collection and use of information obtained by tracking the Internet activity of an individual. H.R. 1528, to protect and enhance consumer privacy, and for other purposes; to Energy & Commerce. H.R. 1841, to protect consumers by requiring reasonable security policies and procedures to protect computerized data containing personal information, and to provide for nationwide notice in the event of a security breach; to Energy & Commerce. H.R. 1939, to provide the Consumer Product Safety Commission with greater authority and discretion in enforcing the consumer product safety laws, and for other purposes; to Energy & Commerce. H.R. 2132, to require the Food and Drug Administration to finalize a standard for broad-spectrum protection in sunscreen products, and for other purposes; to Energy & Commerce. H.R. 2359, to amend title VI of the Federal Food, Drug, and Cosmetic Act to ensure the safe use of cosmetics, and for other purposes; jointly to Energy & Commerce and Education & the Workforce. H.R. 2577, to protect consumers by requiring reasonable security policies and procedures to protect data containing personal information, and to provide for nationwide notice in the event of a security breach. H.R. 2715, to provide the Consumer Product Safety Commission with greater authority and discretion in enforcing the consumer product safety laws, and for other purposes. H.R. 3847, to amend the Federal Food, Drug, and Cosmetic Act to ensure that a medical device is not marketed based on a determination that the device is substantially equivalent to a predicate device that has been recalled, corrected, or removed from the market because of an intrinsic flaw in technology or design that adversely affects safety. H.R. 4262, to amend the Federal Food, Drug, and Cosmetic Act to improve the safety of cosmetics; to Energy & Commerce. H.R. 4395, to amend the Federal Food, Drug, and Cosmetic Act to establish new procedures and requirements for the registration of cosmetic product manufacturing establishments, the submission of cosmetic product and ingredient statements, and the reporting of serious and unexpected cosmetic product adverse events, and for other purposes; to Energy & Commerce. H.R. 6131, to extend the Undertaking Spam, Spyware, and Fraud Enforcement With Enforcers beyond Borders Act of 2006. S. 799, to establish a regulatory framework for the comprehensive protection of personal data for individuals under the aegis of the Federal Trade Commission, and for other purposes; to Commerce. S. 913, to require the Federal Trade Commission to prescribe regulations regarding the collection and use of personal information obtained by tracking the online activity of an individual, and for other purposes; to Commerce. S. 1064, to make effective the proposed rule of the Food and Drug Administration relating to sunscreen drug products, and for other purposes. S. 1151, to prevent and mitigate identity theft, to ensure privacy, to provide notice of security breaches, and to enhance criminal penalties, law enforcement assistance, and other protections against security breaches, fraudulent access, and misuse of personally identifiable information; to Judiciary. S. 1207, to protect consumers by requiring reasonable security policies and procedures to protect data containing personal information, and to provide for nationwide notice in the event of a security breach; to Commerce. S. 1408, to require federal agencies, and persons engaged in interstate commerce, in possession of data containing sensitive personally identifiable information, to disclose any breach of such information. S. 1434, to protect information relating to consumers, to require notice of security breaches, and for other purposes. S. 1535, to protect consumers by mitigating the vulnerability of personally identifiable information to theft through a security breach, providing notice and remedies to consumers in the wake of such a breach, holding companies accountable for preventable breaches, facilitating the sharing of post-breach technical information between companies, and enhancing criminal and civil penalties and other protections against the unauthorized collection or use of personally identifiable information, with an amendment in the nature of a substitute. S. 1652, to amend title 9 of the U.S. Code to prohibit mandatory arbitration clauses in contracts for mobile service. S. 3187, to amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user-fee programs for prescription drugs and medical devices. S. 3333, to require certain entities that collect and maintain personal information of individuals to secure such information and to provide notice to such individuals in the case of a breach of security involving such information, and for other purposes; to Commerce. S. 3410, to extend the Undertaking Spam, Spyware, And Fraud Enforcement With Enforcers beyond Borders Act of 2006, and for other purposes; to Commerce.

Client expense: $110,000 · Firm income: Not reported

H.R. 4395

mr MICHAEL ZARRELLI

Government targets: HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of, U.S. Trade Representative (USTR)

ALTICOR INC.client→ALTICOR INC.

2012 · third_quarter · Consumer Issues/Safety/Products

Open original LDA filing ↗

Cited source text, amounts, lobbyists, and targets

H.R. 611, to foster transparency about the commercial use of personal information, provide consumers with meaningful choice about the collection, use, and disclosure of such information. H.R. 654, to direct the Federal Trade Commission to prescribe regulations regarding the collection and use of information obtained by tracking the Internet activity of an individual. H.R. 1528, to protect and enhance consumer privacy, and for other purposes; to Energy & Commerce. H.R. 1841, to protect consumers by requiring reasonable security policies and procedures to protect computerized data containing personal information, and to provide for nationwide notice in the event of a security breach; to Energy & Commerce. H.R. 1939, to provide the Consumer Product Safety Commission with greater authority and discretion in enforcing the consumer product safety laws, and for other purposes; to Energy & Commerce. H.R. 2132, require the Food and Drug Administration to finalize a standard for broad-spectrum protection in sunscreen products. H.R. 2359, to amend title VI of the Federal Food, Drug, and Cosmetic Act to ensure the safe use of cosmetics, and for other purposes; jointly to Energy & Commerce and Education & the Workforce. H.R. 2577, to protect consumers by requiring reasonable security policies and procedures to protect data containing personal information, and to provide for nationwide notice in the event of a security breach; to Energy & Commerce. H.R. 2715, to provide the Consumer Product Safety Commission with greater authority and discretion in enforcing the consumer product safety laws, and for other purposes; to Energy & Commerce; considered and passed. H.R. 3847, to amend the Federal Food, Drug, and Cosmetic Act to ensure that a medical device is not marketed based on a determination that the device is substantially equivalent to a predicate device that has been recalled, corrected, or removed from the market because of an intrinsic flaw in technology or design that adversely affects safety, and for other purposes. H.R. 4262, to amend the Federal Food, Drug, and Cosmetic Act to improve the safety of cosmetics; to Energy & Commerce. H.R. 4395, to amend the Federal Food, Drug, and Cosmetic Act to establish new procedures and requirements for the registration of cosmetic product manufacturing establishments, the submission of cosmetic product and ingredient statements, and the reporting of serious and unexpected cosmetic product adverse events, and for other purposes; to Energy & Commerce. H.R. 6131, to extend the Undertaking Spam, Spyware, and Fraud Enforcement With Enforcers beyond Borders Act of 2006. S. 799, to establish a regulatory framework for the comprehensive protection of personal data for individuals under the aegis of the Federal Trade Commission, and for other purposes; to Commerce. S. 913, to require the Federal Trade Commission to prescribe regulations regarding the collection and use of personal information obtained by tracking the online activity of an individual, and for other purposes; to Commerce. S. 1064, to make effective the proposed rule of the Food and Drug Administration relating to sunscreen drug products. S. 1151, to prevent and mitigate identity theft, to ensure privacy, to provide notice of security breaches, and to enhance criminal penalties, law enforcement assistance, and other protections against security breaches, fraudulent access, and misuse of personally identifiable information; to Judiciary. S. 1207, to protect consumers by requiring reasonable security policies and procedures to protect data containing personal information, and to provide for nationwide notice in the event of a security breach; to Commerce. S. 1408, to require federal agencies, and persons engaged in interstate commerce, in possession of data containing sensitive personally identifiable information, to disclose any breach of such information; to Judiciary. S. 1434, to protect information relating to consumers, to require notice of security breaches. S. 1535, to protect consumers by mitigating the vulnerability of personally identifiable information to theft through a security breach, providing notice and remedies to consumers in the wake of such a breach, holding companies accountable for preventable breaches, facilitating the sharing of post-breach technical information between companies, and enhancing criminal and civil penalties and other protections against the unauthorized collection or use of personally identifiable information. S. 1652, to amend title 9 of the U.S. Code to prohibit mandatory arbitration clauses in contracts for mobile service; to Judiciary. S. 3187, to amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user-fee programs for prescription drugs and medical devices, to establish user-fee programs for generic drugs and biosimilars. S. 3333, to require certain entities that collect and maintain personal information of individuals to secure such information and to provide notice to such individuals in the case of a breach of security involving such information, and for other purposes. S. 3410, to extend the Undertaking Spam, Spyware, And Fraud Enforcement With Enforcers beyond Borders Act of 2006.

Client expense: $110,000 · Firm income: Not reported

H.R. 4395

mr MICHAEL ZARRELLI

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE

BREAST CANCER PREVENTION PARTNERS (FORMERLY KNOWN AS BREAST CANCER FUND)client→THE RABEN GROUP

2012 · third_quarter · Health Issues

Open original LDA filing ↗

Cited source text, amounts, lobbyists, and targets

Legislation in the 112th H.R. 432, the Ban Poisonous Additives Act of 2011( related Senate Bill, S. 136) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill. Continued: Legislation in the 112th S. 847, the Safe Chemicals Act of 2011 The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. H.R. 2359, the Safe Cosmetics Act of 2011 The Breast Cancer Fund supports this legislation to reform the FDA's regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. H.R.4395, the Cosmetic Safety Amendments Act of 2012 The Breast Cancer Fund opposes this legislation as it would further weaken the FDAs ability to regulate the safety of cosmetics. H.R. 4262, the Cosmetics Safety Enhancement Act of 2012 The Breast Cancer Fund opposes this legislation as it is not strong enough to effectively regulate the safety of cosmetics. H.R. 2521, the Endocrine-Disrupting Chemicals Exposure Elimination act of 2011 (Senate version S. 1361) and H.R. 553 Endocrine Disruptor Screening Enhancement Act of 2011 The Breast Cancer Fund supported this legislation as it would increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer. H.R. 1939: Enhancing CPSC Authority and Discretion Act of 2011. The Breast Cancer Fund lobbied for a provision that ensures that phthalates, when necessary in the manufacture of children's toys, are only used safely. H.R. 3067: Accelerating the End of Breast Cancer Act of 2011. The Breast Cancer Fund supported this legislation as it would increase focus on research to prevent, treat, and end breast caner. S. 3237, the Accelerating the End of Breast Cancer Act of 2012. The Breast Cancer Fund supports this legislation as it would increase focus on research to prevent, treat, and end breast cancer. House and Senate Appropriations - The Breast Cancer Fund contacted House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program, opposing appropriations riders limiting the work of the National Toxicology Program's Report on Carcinogens, and increasing support for health tracking and NIEHS programs related to breast cancer research. Future Legislative Proposals: The Breast Cancer Fund continues to meet with staff from various House and Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products. The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. Regulation and Legislative Intent: FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally. Presidents Cancer Panel Report The Breast Cancer Fund communicated with staff in the Executive Office of the President and the Office of Science and Technology Policy regarding the report and recommendations of the President's Cancer Panel, and continues to encourage ongoing efforts by the Executive Branch to raise awareness about breast cancer risk, prevention, and the environment. P.L. 110-314 - The Consumer Product Safety Commission Inprovement Act The Breast Cancer Fund lobbied in support of the provision that bans the use of phthalates in the manufacture of children's toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and are submitting public comments at various stages of the law's implementation. P.L. 110-354 - Breast Cancer and Environmental Research Act of 2008 This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.

Client expense: Not reported · Firm income: $30,000

H.R.4395

DANIEL PENCHINA KATHARINE HUFFMAN RANDI MOORE ROBERT RABEN

ALTICOR INC.client→ALTICOR INC.

2012 · second_quarter · Consumer Issues/Safety/Products

Open original LDA filing ↗

Cited source text, amounts, lobbyists, and targets

H.R. 611, to foster transparency about the commercial use of personal information, provide consumers with meaningful choice about the collection, use, and disclosure of such information. H.R. 654, to direct the Federal Trade Commission to prescribe regulations regarding the collection and use of information obtained by tracking the Internet activity of an individual. H.R. 1528, to protect and enhance consumer privacy, and for other purposes; to Energy & Commerce. H.R. 1841, to protect consumers by requiring reasonable security policies and procedures to protect computerized data containing personal information, and to provide for nationwide notice in the event of a security breach; to Energy & Commerce. H.R. 1939, to provide the Consumer Product Safety Commission with greater authority and discretion in enforcing the consumer product safety laws, and for other purposes; to Energy & Commerce. H.R. 2132, to require the Food and Drug Administration to finalize a standard for broad-spectrum protection in sunscreen products, and for other purposes; to Energy & Commerce. H.R. 2359, to amend title VI of the Federal Food, Drug, and Cosmetic Act to ensure the safe use of cosmetics, and for other purposes; jointly to Energy & Commerce and Education & the Workforce. H.R. 2577, to protect consumers by requiring reasonable security policies and procedures to protect data containing personal information, and to provide for nationwide notice in the event of a security breach. H.R. 2715, to provide the Consumer Product Safety Commission with greater authority and discretion in enforcing the consumer product safety laws, and for other purposes. H.R. 3847, to amend the Federal Food, Drug, and Cosmetic Act to ensure that a medical device is not marketed based on a determination that the device is substantially equivalent to a predicate device that has been recalled, corrected, or removed from the market because of an intrinsic flaw in technology or design that adversely affects safety. H.R. 4262, to amend the Federal Food, Drug, and Cosmetic Act to improve the safety of cosmetics; to Energy & Commerce. H.R. 4395, to amend the Federal Food, Drug, and Cosmetic Act to establish new procedures and requirements for the registration of cosmetic product manufacturing establishments, the submission of cosmetic product and ingredient statements, and the reporting of serious and unexpected cosmetic product adverse events, and for other purposes; to Energy & Commerce. H.R. 6131, to extend the Undertaking Spam, Spyware, and Fraud Enforcement With Enforcers beyond Borders Act of 2006. S. 799, to establish a regulatory framework for the comprehensive protection of personal data for individuals under the aegis of the Federal Trade Commission, and for other purposes; to Commerce. S. 913, to require the Federal Trade Commission to prescribe regulations regarding the collection and use of personal information obtained by tracking the online activity of an individual, and for other purposes; to Commerce. S. 1064, to make effective the proposed rule of the Food and Drug Administration relating to sunscreen drug products, and for other purposes. S. 1151, to prevent and mitigate identity theft, to ensure privacy, to provide notice of security breaches, and to enhance criminal penalties, law enforcement assistance, and other protections against security breaches, fraudulent access, and misuse of personally identifiable information; to Judiciary. S. 1207, to protect consumers by requiring reasonable security policies and procedures to protect data containing personal information, and to provide for nationwide notice in the event of a security breach; to Commerce. S. 1408, to require federal agencies, and persons engaged in interstate commerce, in possession of data containing sensitive personally identifiable information, to disclose any breach of such information. S. 1434, to protect information relating to consumers, to require notice of security breaches, and for other purposes. S. 1535, to protect consumers by mitigating the vulnerability of personally identifiable information to theft through a security breach, providing notice and remedies to consumers in the wake of such a breach, holding companies accountable for preventable breaches, facilitating the sharing of post-breach technical information between companies, and enhancing criminal and civil penalties and other protections against the unauthorized collection or use of personally identifiable information, with an amendment in the nature of a substitute. S. 1652, to amend title 9 of the U.S. Code to prohibit mandatory arbitration clauses in contracts for mobile service. S. 3187, to amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user-fee programs for prescription drugs and medical devices. S. 3333, to require certain entities that collect and maintain personal information of individuals to secure such information and to provide notice to such individuals in the case of a breach of security involving such information, and for other purposes; to Commerce.

Client expense: $110,000 · Firm income: Not reported

H.R. 4395

mr MICHAEL ZARRELLI

Government targets: HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of, U.S. Trade Representative (USTR)

BREAST CANCER PREVENTION PARTNERS (FORMERLY KNOWN AS BREAST CANCER FUND)client→THE RABEN GROUP

2012 · second_quarter · Health Issues

Open original LDA filing ↗

Cited source text, amounts, lobbyists, and targets

Legislation in the 112th H.R. 432, the Ban Poisonous Additives Act of 2011( related Senate Bill, S. 136) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill. Continued: Legislation in the 112th S. 847, the Safe Chemicals Act of 2011 The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. H.R. 2359, the Safe Cosmetics Act of 2011 The Breast Cancer Fund supports this legislation to reform the FDA's regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. H.R.4395, the Cosmetic Safety Amendments Act of 2012 The Breast Cancer Fund opposes this legislation as it would further weaken the FDAs ability to regulate the safety of cosmetics. H.R. 4262, the Cosmetics Safety Enhancement Act of 2012 The Breast Cancer Fund opposes this legislation as it is not strong enough to effectively regulate the safety of cosmetics. H.R. 2521, the Endocrine-Disrupting Chemicals Exposure Elimination act of 2011 (Senate version S. 1361) and H.R. 553 Endocrine Disruptor Screening Enhancement Act of 2011 The Breast Cancer Fund supported this legislation as it would increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer. H.R. 1939: Enhancing CPSC Authority and Discretion Act of 2011. The Breast Cancer Fund lobbied for a provision that ensures that phthalates, when necessary in the manufacture of children's toys, are only used safely. H.R. 3067: Accelerating the End of Breast Cancer Act of 2011. The Breast Cancer Fund supported this legislation as it would increase focus on research to prevent, treat, and end breast caner. S. 3237, the Accelerating the End of Breast Cancer Act of 2012. The Breast Cancer Fund supports this legislation as it would increase focus on research to prevent, treat, and end breast cancer. House and Senate Appropriations - The Breast Cancer Fund contacted House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program as well as support for health tracking and NIEHS programs related to breast cancer research. Future Legislative Proposals: The Breast Cancer Fund continues to meet with staff from various House and Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products. The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. Regulation and Legislative Intent: FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally. Presidents Cancer Panel Report The Breast Cancer Fund communicated with staff in the Executive Office of the President and the Office of Science and Technology Policy regarding the report and recommendations of the President's Cancer Panel, and continues to encourage ongoing efforts by the Executive Branch to raise awareness about breast cancer risk, prevention, and the environment. P.L. 110-314 - The Consumer Product Safety Commission Inprovement Act The Breast Cancer Fund lobbied in support of the provision that bans the use of phthalates in the manufacture of children's toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and are submitting public comments at various stages of the law's implementation. P.L. 110-354 - Breast Cancer and Environmental Research Act of 2008 This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.

Client expense: Not reported · Firm income: $30,000

H.R.4395

DANIEL PENCHINA KATHARINE HUFFMAN RANDI MOORE ROBERT RABEN

Government targets: Consumer Product Safety Commission (CPSC), Environmental Protection Agency (EPA), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE

Cosmetic Safety Amendments Act of 2012

Summary

Lobbying filings that explicitly cite this bill (50)

Similar Bills (AI)